Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics announced that Phase II MAvERIC results for CardiolRx™ in recurrent pericarditis were accepted for publication in the Journal of the American Heart Association. The study demonstrated rapid reductions in pain and inflammation with a favorable safety profile, providing clinical validation for the ongoing pivotal Phase III MAVERIC trial which is over 75% enrolled.
Key figures
- Drug Name
- CardiolRx™
- Phase Of Trial
- Phase II
- Enrollment percentage
- > 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.